Hyderabad: Aurobindo Pharma on Wednesday informed the bourses that its subsidiary TheraNym Biologics Pvt Ltd has fortified its collaboration with Merck Sharpe & Dohme Singapore Trading Pte Ltd (MSD) by executing an additional product schedule under their existing contract manufacturing organization (CMO) agreement of May 2024. Under the newly signed product schedule, TheraNym Biologics will be investing around $150 million to $175 million for setting up a greenfield large-scale drug substance manufacturing facility equipped with mammalian cell culture bioreactors of around 60,000 litres along with the requisite advanced downstream purification infrastructure for drug substance production. TheraNym will build the manufacturing facility, called TheraNym Unit 2, to manufacture the products and supply to MSD as per the arrangement, Aurobindo Pharma said. The facility will manufacture biologics for the domestic as well as international markets and will further expand the Aurobindo arm's existing CMO relationship with MSD for biologicals.
Ready to Make a Smarter Property Decision? Build Your Legacy with TOI Homes.
Swati Bharadwaj is a business journalist with 30 years of experie...
Read MoreSwati Bharadwaj is a business journalist with 30 years of experience covering a host of sectors – right from technology, GCCs, talent, cybersecurity, pharma & biotech, aerospace & defence, BFSI, gems & jewellery to automotive, hospitality, infrastructure, retail, among others. She has worked with TOI and ET across multiple cities such as Hyderabad, Bengaluru, Pune and Ahmedabad.
Read Less
Start a Conversation
Post comment